Genome research in pre-dementia stages of Alzheimer's disease

Moreno‐Grau, Sonia; Ruiz, Agustín

doi:10.1017/erm.2016.12

Cited by 17 publications

(18 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding APOE ε4 genotype and incident MCI, APOE ε4–positive women with SCD showed strong associations with MCI 5 years later, whereas APOE ε4–negative women with SCD did not. This is in line with the literature as APOE ε4 is a genetic risk factor for AD dementia and conversion from its earlier stages [29]. APOE ε4–positive men with SCD and especially APOE ε4–negative men with SCD showed strong associations with incident MCI.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women

Müller-Gerards

Weimar

Abramowski

et al. 2019

Alz & Dem Diag Ass & Dis Mo

View full text Add to dashboard Cite

Introduction Possible joint effects of subjective cognitive decline (SCD) and apolipoprotein E ( APOE ) ε4 genotype on incident mild cognitive impairment (MCI) were examined for men and women separately. Methods Cognitively normal participants with and without SCD were included from the first follow-up examination of the population-based Heinz Nixdorf Recall study. Sex-stratified logistic regression models estimated main effects and interactions (additive, multiplicative) of SCD at the first follow-up (yes+/no−) and APOE ε4 (positive+/negative−) groups for MCI 5 years later. Results Odds for MCI 5 years later were higher in SCD/ APOE ε4 group +/+ than the sum of groups +/− and −/+ in women, with a trend for positive interaction. Odds for incident MCI in men was highest in group +/−, with no interaction effect. Discussion Our findings indicate that APOE ε4 may play an important role in the association of SCD and incident MCI, especially considering sex. Further studies need to examine these associations with larger sample sizes.

show abstract

Section: Discussionsupporting

confidence: 91%

“…with SCD did not. This is in line with the literature as APOE ε4 is a genetic risk factor for AD dementia and conversion from its earlier stages [29]. APOE ε4-positive men with SCD and especially APOE ε4-negative men with SCD showed strong associations with incident MCI.…”

Section: Discussionsupporting

confidence: 85%

Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women

Müller-Gerards

Weimar

Abramowski

et al. 2019

Alz & Dem Diag Ass & Dis Mo

View full text Add to dashboard Cite

show abstract

“…Moreno-Grau and Ruiz [14] included 6,824 patients from 8 studies in their meta-analysis. The significant association between APOE e4 and SCD disappeared when a random model was used.…”

Section: Discussionmentioning

confidence: 99%

“…However, 2 case-control studies conducted by Verdile et al [12] and Caselli et al [13] showed that the prevalence of APOE e4 did not significantly differ between healthy controls and SCD groups. In May 2016, Moreno-Grau and Ruiz [14] reported that APOE e4 was a genetic risk factor for the development of SCD (OR 1.151 [1.015–1.304]; p = 0.028). However, their meta-analysis included subjects with non-SCD cognitive decline, whose mean mini-mental state evaluation scores were <25 [15].…”

Section: Introductionmentioning

confidence: 99%

Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

Background and Purpose: Subjective cognitive decline (SCD) is a condition associated with increased risk of Alzheimer’s disease. This study performs a meta-analysis to estimate the prevalence of the Apolipoprotein E e4 (APOE e4) allele in SCD and the association of APOE e4 with SCD. Methods: The MEDLINE, EMBASE, and Cochrane Library databases were searched. Meta-analyses were conducted using STATA 12.0 software. When significant heterogeneity was present (I² >50% and p < 0.05), we conducted stratified and meta-regression analyses to explore possible reasons for heterogeneity. Results: We selected a total of 28 studies that were conducted in Australia, the United States, northern Europe, middle Europe, southern Europe, and Asia. The sample size of the SCD group was 6,044. Thirteen studies included a healthy control group (total control cohort of 3,822), whereas the remaining 15 studies were single-arm studies of SCD groups. The APOE e4 allele was associated with SCD (OR 1.12 [1.00–1.25]; p = 0.04). The pooled estimate for APOE e4 carrier prevalence was 32% (95% CI 28–35). Due to the significant heterogeneity in prevalence estimates, we performed stratified and meta-regression analyses and found that age and northern European residency were significantly associated with heterogeneity. Conclusion: The results of this meta-analysis indicate a weak association between APOE e4 and SCD. Age and northern European residency are the critical factors that determine heterogeneity in the APOE e4-associated prevalence of SCD.

show abstract

“…La enfermedad de Alzheimer tiene una heredabilidad estimada de alrededor del 70% (6). Hasta la fecha, más de 20 genes se han asociado con la enfermedad de Alzheimer y, de ellos, solo tres están relacionados con las formas familiares de inicio temprano de la enfermedad: APP, PSEN1 y PSEN2 (7).…”

Section: Introducción Y Justificaciónunclassified

Proyecto CRIDECO: Cribado de deterioro cognitivo en farmacia comunitaria a partir de la queja subjetiva de memoria

Catalá¹,

Royo²,

Molinera³

et al. 2018

View full text Add to dashboard Cite

RESUMENObjetivo: desarrollar un programa de cribado de deterioro cognitivo (DC) en mayores de 50 años. Con la finalidad de que el servicio profesional farmacéutico sea más costo-efectivo utilizaremos un árbol de decisión para la selección del paciente.Además, se pretende valorar la importancia de la dieta mediterránea y el consumo de antioxidantes en la prevención del deterioro cognitivo y estudiar marcadores genéticos de riesgo de enfermedad de Alzheimer.Método: para ello se diseña un estudio observacional transversal mediante entrevista personal estructurada en pacientes que muestren indicios de pérdida de memoria. El estudio de captación se realizará en farmacias desde septiembre 2018 hasta septiembre de 2019. Los pacientes con puntuación en los test con posible DC se remitirán a atención primaria, previa presentación del proyecto a coordinación médica. Se perseguirá el resultado del diagnóstico obtenido en atención primaria y/o especializada. Se utilizarán como test de cribado el Memory Impairment Screening (MIS), Short Portable Mental State Questionnaire (SPMSQ) de Pfeiffer, el Fluidez Verbal Semántica (FVS) y siempre que sea posible el Test del Informador (TIN). Se define deterioro cognitivo por MIS ≤4; SPMSQ ≥ 3 (para analfabetos ≥ 4); FVS ≤10 palabras y el valor del TIN >57. A su vez se recogen una muestra de saliva del paciente, para estudio genético, y datos de nutrición para valorar la importancia de la dieta mediterránea y de los alimentos antioxidantes en la prevención del DC. CRIDECO Project. Screening for cognitive impairment in community pharmacy based on subjective memory complaint ABSTRACTThe aim of this study is to develop a screening program for cognitive impairment (CI) in people older than 50 year old. In order to make the pharmaceutical professional service more cost-effective, we will use a decision tree for patient's selection.In addition, to assess the importance of the Mediterranean diet and the consumption of antioxidants in the prevention of cognitive deterioration and study genetic markers of risk of Alzheimer's disease.

show abstract

Genome research in pre-dementia stages of Alzheimer's disease

Cited by 17 publications

References 142 publications

Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women

Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women

Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

Proyecto CRIDECO: Cribado de deterioro cognitivo en farmacia comunitaria a partir de la queja subjetiva de memoria

Contact Info

Product

Resources

About